{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:59:34Z","timestamp":1740135574068,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Besides the clinical benefit of crizotinib in ALK-rearranged metastatic non-small cell lung cancer (NSCLC), concerns about its hepatotoxicity have arisen. It is not clear whether this is a drug class side effect or if the use of other selective ALKs inhibitors is safe after this serious adverse event. While evidence from clinical trials is scarce, reports of treatment after crizotinib-induces hepatitis may add to clinical decision.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Herein, we report a case of acute hepatitis induced by crizotinib in a 32-years-old female diagnosed with metastatic NSCLC, harboring the ALK-rearrangement. After 60\u00a0days of crizotinib therapy, the patient presented with acute hepatitis, diagnosed after investigation of non-specific symptoms, such as nausea and fatigue. Serum aspartate aminotransferase and alanine aminotransferase levels had increased from baseline to 3010\u00a0IU\/L and 9145\u00a0IU\/L, respectively. Total bilirubin increased up to 7.91\u00a0mg\/dL, but she did not develop liver failure. After crizotinib discontinuation, a gradual hepatic function recovery occurred. Unfortunately, during the period without specific oncology treatment, her disease showed an unequivocal progression. Therefore, she started on alectinib with great response, and no liver function alteration recurred.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case suggests that alectinib, even belonging to the same drug class, could be used as an alternative agent when crizotinib is the etiology of liver damage, but more robust evidence has awaited.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-020-01390-6","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T09:36:17Z","timestamp":1611826577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Successful treatment with alectinib after crizotinib-induced hepatitis in ALK-rearranged advanced lung cancer patient: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Fl\u00e1via Amaral","family":"Duarte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo Brand","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1via Rocha","family":"Paes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2016-5593","authenticated-orcid":false,"given":"Paulo Henrique Costa","family":"Diniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena Fl\u00e1via Cuba de Almada","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"key":"1390_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin. 2013;63:11\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1390_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","volume":"12","author":"W Pao","year":"2011","unstructured":"Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175\u201380.","journal-title":"Lancet Oncol"},{"key":"1390_CR3","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","volume":"6","author":"JG Christensen","year":"2007","unstructured":"Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnel SR, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large cell lymphoma. Mol Cancer Ther. 2007;6:3314\u201322.","journal-title":"Mol Cancer Ther"},{"key":"1390_CR4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","volume":"13","author":"DR Camidge","year":"2012","unstructured":"Camidge DR, Bang YL, Kwak EL, Ifrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011\u20139.","journal-title":"Lancet Oncol"},{"key":"1390_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, Seto T, Crin\u00f3 L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:23\u201394.","journal-title":"N Engl J Med"},{"key":"1390_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S1470-2045(11)70232-7","volume":"12","author":"AT Shaw","year":"2011","unstructured":"Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12:1004\u201312.","journal-title":"Lancet Oncol"},{"key":"1390_CR7","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.3748\/wjg.14.6774","volume":"14","author":"K Tajiri","year":"2008","unstructured":"Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008;14:6774\u201385.","journal-title":"World J Gastroenterol"},{"key":"1390_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1055\/s-0029-1240002","volume":"29","author":"LN Bell","year":"2009","unstructured":"Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis. 2009;29:337\u201347.","journal-title":"Semin Liver Dis"},{"key":"1390_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/11207680-000000000-00000","volume":"72","author":"MP Curran","year":"2012","unstructured":"Curran MP. Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs. 2012;72:99\u2013107.","journal-title":"Drugs"},{"key":"1390_CR10","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208434s003lbl.pdf\/. Accessed 29 Oct 2019"},{"issue":"10","key":"1390_CR11","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jtho.2017.06.070","volume":"12","author":"JC Yang","year":"2017","unstructured":"Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, et al. Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of Alectinib in ALK-positive non-small cell lung cancer. J Thorac Oncol. 2017;12(10):1552.","journal-title":"J Thorac Oncol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01390-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-020-01390-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01390-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T09:41:24Z","timestamp":1611826884000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-01390-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1390"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-01390-6","relation":{},"ISSN":["1471-2466"],"issn-type":[{"type":"electronic","value":"1471-2466"}],"subject":[],"published":{"date-parts":[[2021,1,28]]},"assertion":[{"value":"27 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from the patient. Ethics approval is not applicable to case reports.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Duarte reports personal fees and non-financial support from F. Hoffmann\u2013La Roche AG, outside the submitted work;.Dr. Rodrigues reports personal fees from F. Hoffmann\u2013La Roche AG, AstraZeneca PLC, Johnson and Johnson, DePuy Synthes and Medtronic, outside the submitted work; Dr.Paes reports non-financial support from Pfizer, Inc., outside the submitted work; Dr. Diniz has nothing to disclose; Dr. Almada reports personal fees and non-financial support from F. Hoffmann-La Roche AG and Astrazeneca, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}